Search

Your search keyword '"Chan, At"' showing total 6,698 results

Search Constraints

Start Over You searched for: Author "Chan, At" Remove constraint Author: "Chan, At" Journal blood Remove constraint Journal: blood
6,698 results on '"Chan, At"'

Search Results

2. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

3. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

4. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML

5. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

6. Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

8. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

10. Single-cell landscape of idiopathic multicentric Castleman disease in identical twins

11. Prevalence and significance of DDX41 gene variants in the general population

12. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

14. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia

15. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

17. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

19. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

20. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

24. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

27. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML

29. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

30. Motive and opportunity: MYCrearrangements in high-grade B-cell lymphoma with MYCand BCL2rearrangements (an LLMPP study)

31. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

32. Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

33. Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

34. Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

36. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

40. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation

41. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

42. Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments

44. A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

46. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

47. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

48. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

49. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

50. Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Catalog

Books, media, physical & digital resources